Enrichment method and application of quinoid chalcone dimer compounds in safflower carthamus
Through methanol or ethanol extraction and macroporous adsorption resin column chromatography technology, the quinone chalone dimer compounds in safflower were successfully enriched, solving the problem of difficulty in extraction, and achieving significant pharmacological activity and anticoagulation Blood function.
Patent Information
- Application Number
- CN202410785350.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-06-18
- Publication Date
- 2024-11-08
AI Technical Summary
The prior art is difficult to effectively enrich the quinone chalone dimer compounds in safflower, resulting in the failure to fully develop its pharmacological potential, and it has the characteristics of thermal instability, making it difficult to extract efficiently.
Safflower is extracted using methanol or ethanol, followed by macroporous adsorption resin column chromatography, eluting through pure water and aqueous ethanol solution of different concentrations, collecting 10% to 50% aqueous ethanol solution eluent to obtain enriched quinone chalone Dimer compounds.
It significantly increases the content of quinone chalone dimer compounds, provides active ingredients for pharmacological research, and exerts anticoagulation functions by activating endogenous, common coagulation pathways and exogenous coagulation systems, with Significantly improves plasma fibrinolytic enzyme activity and anti-platelet aggregation.
Smart Images

Figure CN118908946A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of natural compound enrichment methods, and in particular to an enrichment method and application of quinone chalcone dimer compounds in safflower. Background Art
[0002] Safflower is the dried tubular flower of Carthamus tinctorius L., a plant of the genus Carthamus in the Asteraceae family. It is widely used clinically to treat various diseases of poor blood circulation or blood stasis in various disciplines, such as cerebral thrombosis, hypertension, traumatic injuries, joint pain, coronary heart disease and angina pectoris. The chemical components isolated from safflower are mainly flavonoids (specific quinone chalcone), alkaloids, lignans, sterols, organic acids and polyacetylenes. Among them, flavonoids and quinone chalcone compounds are the main active ingredients in safflower. The structural characteristics of quinone chalcone compounds are that the A ring of chalcone compounds is oxidized to quinone or quinone analogs, all of which exist in the form of glycosides and are mainly carbonylated, mainly red pigment and yellow pigment. Quinone chalcone compounds usually exist in the form of single molecule compounds, and a few exist in the form of bimolecular polymerization. In the pharmacological research of safflower flavonoids, a single monomer compound, such as hydroxysafflower yellow A (HSYA), is often found, while other compounds, such as anhydrosafflower yellow B (anHSYB), safflower yellow B (SYB), safflower quinone A, etc., are mostly ignored. It can be seen that the pharmacological potential of safflower has not been fully developed, and further research on chalcone dimer compounds with potential biological activity is of great significance.
[0003] Safflower yellow pigment is the main water-soluble active ingredient of safflower, and is usually extracted by solvent extraction, enzyme method, ultrasonic assisted extraction method, microwave extraction method, and separated by macroporous adsorption resin method, ultrafiltration method, etc.; while red pigment is a medium polar component, and the main extraction methods include solvent extraction, enzyme method, ultrasonic extraction method, etc., and is separated by two-phase system method, alkali extraction and acid precipitation method, etc. According to current research, this type of component has a high polarity due to the presence of multiple hydroxyl groups. Except for HSYA, the content of the remaining quinone chalcone is lower than that of other common flavonoid oxygen glycosides, and it is thermally unstable, so it is not easy to enrich it with existing methods. Summary of the invention
[0004] In view of the above technical problems, the present invention provides an enrichment method and application of quinone chalcone dimer compounds in safflower. The enrichment method provided by the present invention can enrich quinone chalcone dimer compounds as the main component from safflower, which can be used for pharmacological research of quinone chalcone dimer compounds in safflower; the extract has significant anticoagulant activity and can be used for in vitro anticoagulation or preparation of antiplatelet aggregation drugs.
[0005] In order to achieve the above-mentioned object of the invention, the present invention adopts the following technical solutions:
[0006] The first aspect of the present invention provides a method for enriching quinone chalcone dimer compounds in safflower, which specifically comprises the following steps:
[0007] S1. extracting safflower with methanol or ethanol, and drying the obtained extract to obtain safflower alcohol extract;
[0008] S2. Performing column chromatography on the safflower alcohol extract using a macroporous adsorption resin, eluting with pure water and 10% to 50% v / v ethanol aqueous solution in sequence, collecting the eluate eluted with 10% to 50% v / v ethanol aqueous solution, and drying to obtain; the macroporous adsorption resin is HPD100 or D4020 macroporous adsorption resin.
[0009] The product obtained by the above-mentioned enrichment method has a high proportion of quinone chalcone dimer compounds, which can provide quinone chalcone dimer active ingredients for the pharmacological activity research of safflower. The product obtained by this method can significantly increase the activity of plasma fibrinolytic enzyme and resist platelet aggregation, and can be used to prepare drugs for anticoagulation by increasing the activity of plasma fibrinolytic enzyme and / or resisting platelet aggregation.
[0010] In combination with the first aspect, the concentration of methanol or ethanol in S1 is not less than 30% v / v.
[0011] Preferably, the concentration of methanol or ethanol in S1 is 50% to 80% v / v.
[0012] Preferably, ethanol is used to extract safflower in S1. Ethanol is less toxic than methanol and is safer to use.
[0013] In combination with the first aspect, the macroporous adsorption resin in S2 is HPD100 macroporous adsorption resin. It has been experimentally verified that the number of peaks with a mass number greater than 950 extracted by the HPD100 macroporous adsorption resin is relatively large, and the mass number>950 in the HPD100 fraction accounts for the largest proportion and the strongest response intensity is close to the response intensity of the corresponding mass number in the total extract.
[0014] In combination with the first aspect, the concentration of the ethanol aqueous solution in S2 is 40% v / v. Experimental verification shows that the total chalcone and chalcone dimer components contained in the eluate of 40% v / v ethanol aqueous solution are the highest, and the content of other components is small, and the eluate of 40% v / v ethanol aqueous solution has more significant anticoagulant activity.
[0015] The second aspect of the present invention provides a safflower extract having anticoagulant activity, wherein the safflower extract is prepared according to the above-mentioned enrichment method.
[0016] The third aspect of the present invention provides the use of the safflower extract in the preparation of anticoagulant drugs.
[0017] Experimental studies have found that anhydrosafflower yellow B (anHSYB), a representative compound among quinone chalcone dimer compounds, can exert anticoagulant function by activating the extrinsic coagulation system and the common coagulation pathway. According to the enrichment method provided by the present invention, a safflower extract rich in quinone chalcone dimer compounds can be prepared, which can exert anticoagulant function by activating the endogenous, common coagulation pathway and extrinsic coagulation system at the same time, and has the effect of significantly improving the activity of plasma fibrinolytic enzyme. In addition, it has been experimentally verified that the safflower extract that can be prepared by the enrichment method provided by the present invention has an anti-aggregation effect on platelets. Therefore, the safflower extract can be used to prepare anticoagulant drugs.
[0018] In combination with the third aspect, the anticoagulant drug is an in vitro anticoagulant drug.
[0019] In conjunction with the third aspect, the anticoagulant drug is a drug that increases the activity of plasma fibrinolytic enzyme.
[0020] In combination with the third aspect, the anticoagulant drug is an antiplatelet aggregation drug.
[0021] The beneficial effects of the present invention are as follows: the present invention provides a method for enriching quinone chalcone dimer compounds in safflower, and the proportion of quinone chalcone dimer compounds in the obtained product is relatively high, which can be used to provide quinone chalcone dimer active ingredients for the pharmacological activity research of safflower. The safflower extract prepared by the method can simultaneously activate the endogenous, common coagulation pathways and exogenous coagulation systems to exert anticoagulant function, has the effect of significantly improving the activity of plasma fibrinolytic enzyme, and can achieve good antiplatelet aggregation effect at a relatively low concentration, so it can be used to prepare anticoagulant drugs. BRIEF DESCRIPTION OF THE DRAWINGS
[0022] Figure 1 is the BPI diagram of m / z 720-1300 in each fraction of safflower of the same concentration in Test Example 1 of the present invention (red represents chalcone dimer class, purple represents chalcone and flavonoid dimer class, blue represents flavonoid dimer class, and black represents other classes);
[0023] Figure 2 It is the separation of dimers (mass number>950) in the best fractions of 32 component mass numbers extracted by column chromatography using six fillers in Test Example 2 of the present invention;
[0024] Figure 3 It is a comparison of the responses of the target components m / z 1115, 1043 and 955 of the fractions after the six column chromatograms were combined in Test Example 2 of the present invention;
[0025] Figure 4 It is a comparison of the responses of the target components m / z 1115, 1043 and 955 of the fractions after the three column chromatograms were combined in Test Example 2 of the present invention;
[0026] Figure 5 It is a comparison of the responses of the target components m / z 955 and 1043 of the fractions after the HPD100 and D4020 column chromatograms were combined in Test Example 2 of the present invention;
[0027] Figure 6 is a graph showing the change trend of platelet aggregation rate over time in Example 6 of the present invention (mean±SD, n=3);
[0028] Figure 7 The platelet aggregation rate of different fractions of safflower at the same concentration in Example 6 of the present invention (mean±SD, n=3) (compared with the blank control group: * P<0.05, ** P<0.01, compared with 40% ethanol eluate: # P<0.05, ## P<0.01);
[0029] Figure 8 The platelet aggregation rate of the representative components of safflower at the same concentration in Example 6 of the present invention (mean±SD, n=3) (compared with the blank group: * P<0.05, ** P<0.01, compared with kaempferol: # P<0.05, ## P<0.01);
[0030] Fig. 9 It is the platelet aggregation inhibition rate of each experimental group with different concentrations of safflower in Example 6 of the present invention (mean±SD, n=3). DETAILED DESCRIPTION
[0031] In order to make the purpose, technical scheme and advantages of the present invention clearer, the present invention is further described in detail below in conjunction with specific embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative work fall within the scope of protection of the present invention.
[0032] The chemical composition and pharmacological activity of safflower have always attracted much attention, especially its main active ingredient flavonoids, but its unique main active ingredient chalcone dimer compounds have been reported less, and it is necessary to study them to fully develop the pharmacological potential of safflower. However, chalcone dimer compounds have the characteristics of large polarity, low content and easy destruction by heat, and are not easy to enrich. In view of this technical problem, the present invention constructs a method for efficiently enriching quinone chalcone dimer compounds in safflower for the first time. In the product obtained by the enrichment method, quinone chalcone dimer compounds account for a high proportion, which can be used to provide quinone chalcone dimer active ingredients for the pharmacological activity research of safflower. And the product obtained by this method has the effect of improving plasma fibrinolytic enzyme activity and anti-platelet aggregation, and can be used to prepare a drug for anti-coagulation by improving plasma fibrinolytic enzyme activity and / or anti-platelet aggregation.
[0033] The embodiments of the present invention also provide the anticoagulant activity and antiplatelet aggregation activity of the product obtained by the enrichment method.
[0034] The following is further described with reference to specific embodiments.
[0035] The main instruments used in the following examples are:
[0036] Agilent 1290 Infinity II / 6550 QTOF high-resolution liquid spectrometer (Agilent, Germany); Waters I-Class UPLC / Vion TM IM-QTOF high-resolution ion mobility liquid spectrometer (Milford, MA, USA); Agilent 1260 InfinityⅡ / 6125B liquid spectrometer (Agilent, California, USA); Waters I-Class UPLC / QDA liquid spectrometer (Milford, MA, USA); Agilent 1260 InfinityⅡ high-performance liquid chromatograph (Agilent, California, USA); Agilent 1290 ultra-high performance liquid chromatograph (Agilent, California, USA); C3510 fully automatic coagulation analyzer (Beijing Mindray Medical Device Co., Ltd.); multifunctional microplate reader (Tecan, Switzerland); Milli-Q Integral 5 water purifier (Millipore, USA).
[0037] The reagents and medicinal materials used in the following examples are: acetonitrile, methanol, formic acid (Fisher, Fair lawn, NJ, USA), all of which are LC-MS grade; chromatographic grade acetonitrile and methanol for extraction and separation (Tianjin Concord Technology Co., Ltd.); analytical grade 95% ethanol and anhydrous ethanol (Concord); D101, AB-8, X-5, HPD200A, ADS-7, D4020, HPD100, MCI, ADS-17 macroporous adsorption resins (Cangzhou Baoen Adsorption Material Co., Ltd.); ultrapure water from Milli-Q Integral 5. Water purification system (Millipore, Bedford, MA, USA); sodium hydroxide (Tianjin Jinke Fine Chemical Research Institute); sodium chloride, potassium chloride (Tianjin Huihang Chemical Technology Co., Ltd.); sodium bicarbonate (Shanghai Yien Chemical Technology Co., Ltd.); 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) (Tianjin Aoshi Technology Development Co., Ltd.); bovine serum albumin (BAS) (Tianjin Kaimart Chemical Technology Co., Ltd.); glucose (Shanghai Myril Biochemical Technology Co., Ltd.); anhydrous calcium chloride (Tianjin Guangfu Technology Development Co., Ltd.); prostaglandin E1 (PGE1) (Beijing Myrida Technology Co., Ltd.) ; Sodium dihydrogen phosphate, ticareg (Shanghai Dibai Chemical Technology Co., Ltd.); adenosine diphosphate (ADP) (Shanghai Yuanye Biotechnology Co., Ltd.); DMSO solution (Tianjin Solomon Biotechnology Co., Ltd.); activated partial thromboplastin time (APTT) assay kit (batch number 230208000), thrombin time (TT) assay kit (batch number 230400300), prothrombin time (PT) assay kit (batch number Y23091301), fibrinogen (FIB) assay kit (batch number 230806800), calcium chloride reagent (batch number 221007000) (Shanghai Changdao Biotechnology Co., Ltd.).
[0038] The experimental animals used in the following examples are SPF male SD rats, weighing 360-420 g, purchased from the Experimental Animal Center of Tianjin University of Traditional Chinese Medicine, with the experimental animal qualification certificate number: SYXK (Jin) 2020-0005. The experiment started after seven days of adaptive feeding.
[0039] Example 1
[0040] This embodiment provides a method for enriching quinone chalcone dimer compounds in safflower. The specific steps are:
[0041] S1. Soak 450g of safflower powder that has passed through a No. 3 sieve in 4.5L of 50% v / v ethanol aqueous solution for 24h, extract it by ultrasonic (1130W, 25kHz) in a 40℃ water bath for 1h, extract it by ultrasonic (1130W, 25kHz) for 30min with 10 times the amount of 50% v / v ethanol aqueous solution for the second time, filter it with gauze after combining the extracts, remove the residue from the filtrate by suction filtration, concentrate the filtrate after the second filtration under reduced pressure with a rotary evaporator (set to 40℃) to a non-alcohol extract, and freeze-dry it to obtain safflower alcohol extract. The extraction rate is 24.31%.
[0042] S2. Take about 250mL of HPD100 macroporous adsorption resin, soak it in 95% v / v ethanol aqueous solution for 24h for pretreatment, wet pack it into a column, the column height is 3 / 4 column (specification: inner diameter is 4cm, column height is 32cm), remove bubbles from the macroporous adsorption resin, slowly put it into the column, make the column surface flat, wash it with 95% v / v ethanol, 80% v / v ethanol, 60% v / v ethanol, 40% v / v ethanol, 20% v / v ethanol aqueous solution and pure water in descending gradient until there is no turbidity and no alcohol taste. Soak it in water and let it stand for 30min. 18 g of safflower alcohol extract obtained by S1 was ultrasonically dissolved with 15 mL of pure water, added to a HPD100 macroporous adsorption resin column (inner diameter 2.0 cm, column height 32 cm), and adsorbed for 2 h, eluted with 2 L of pure water and 40% v / v ethanol aqueous solution in sequence. The eluate was collected, concentrated under reduced pressure below 40°C, and then freeze-dried into a powder to obtain 4.9342 g of powder, with a calculated yield of 6.66%.
[0043] Example 2
[0044] This embodiment provides a method for enriching quinone chalcone dimer compounds in safflower. The specific steps are basically the same as those in Example 1, except that the solvent for ultrasonic extraction in S1 is 30% v / v ethanol aqueous solution.
[0045] Example 3
[0046] This embodiment provides a method for enriching quinone chalcone dimer compounds in safflower. The specific steps are basically the same as those in Example 1, except that the solvent for ultrasonic extraction in S1 is 80% v / v ethanol aqueous solution.
[0047] Example 4
[0048] This embodiment provides a method for enriching quinone chalcone dimer compounds in safflower. The specific steps are basically the same as those in Example 1, except that the solvent for ultrasonic extraction in S1 is 95% v / v ethanol aqueous solution.
[0049] Test Example 1
[0050] On the basis of Example 1, after elution with 40% v / v ethanol aqueous solution, S2 was eluted with 50%, 60%, and 95% v / v ethanol aqueous solutions in sequence, and the eluate was collected, concentrated under reduced pressure below 40°C, and then freeze-dried into a powder.
[0051] The ethanol extract of safflower obtained in S1 of Example 1, the 40% v / v ethanol aqueous solution eluate obtained in S2 of Example 1, and the eluate eluted with 50%, 60%, and 95% v / v ethanol aqueous solution were accurately weighed, and different proportions of methanol were added to dissolve them to prepare the test solution, which was centrifuged at 14,000 rpm (11,481×g) and 4°C for 10 min, and the supernatant was taken and stored for later use. The above samples were analyzed by Waters I-Class UPLC / Vion TM Detection was performed using IM-QTOF ion mobility high-resolution LC-MS, Agilent 1290 ultra-high performance liquid chromatography and Agilent 1290 Infinity II / 6550QTOF high-resolution LC-MS.
[0052] Waters I-Class UPLC / Vion TM IM-QTOF High Resolution Ion Mobility LC-MS Parameter Settings: Using Scanning Method HDMS E Data acquisition was performed in negative ion mode. The electrospray ion source parameters were set as follows: capillary voltage 1.5 kV (ESI-); cone voltage 80 V (ESI-); source offset, 80 V; source temperature, 120 °C; desolvation gas temperature (N2), 500 °C; desolvation gas flow (N2), 800 L / h; cone gas flow (N2), 50 L / h. HDMS E Set the scan time to 0.3 seconds (MS 1 ) scan range m / z 720-1300 and ramp collision energy (RCE) was set to 40-60 eV (ESI-). Default parameters for traveling wave ion mobility separation were defined and CCS calibration was performed according to the manufacturer's guidelines using a calibrant mixture. MS data calibration was performed by continuous infusion of leucine enkephalin solution at a flow rate of 10 μL / min.
[0053] Parameter settings of Agilent 1290 ultra-high performance liquid chromatograph: the chromatographic column is ACQUITY HSS T3 (2.1×100mm, 1.8μm); column temperature 30℃; mobile phase A was 0.1% formic acid in water, mobile phase B was CH3CN, and elution was performed according to the gradient elution program: 0-2min, 3%-5% (B); 2-4min, 5%-10% (B); 4-7min, 10%-11% (B); 7-9min, 11%-12% (B); 9-12min, 12%-13% (B); 12-25min, 13%-16% (B); 25-26min, 16%-18% (B); 26-35min , 18%-20% (B); 35-45min, 20%-21% (B); 45-47min, 21%-22% (B); 47-48min, 22%-24% (B); 48-58min, 24%-25% (B); 58-60min, 25%-28% (B); 60-68min, 28%-30% (B); 68-75min, 30%-40% (B); 75-77min, 40%-95% (B); flow rate 0.4mL / min, injection volume 3μL, detection wavelength 405nm.
[0054] The parameter settings of Agilent 1290 Infinity II / 6550 QTOF high-resolution LC-MS instrument are as follows: the chromatographic conditions are consistent with the detection conditions of the Agilent 1290 ultra-high performance liquid chromatograph mentioned above, and the mass spectrometry parameters of 6550 QTOF are as follows: the scanning method AutoMSMS is used for negative ion mode data acquisition. Ultra-high purity nitrogen (N2) and nitrogen generated by a nitrogen generator were used as collision gas and sheath gas / auxiliary gas, respectively; the gas temperature was set to 200°C, the drying gas flow rate was 12 L / min, the nebulizer pressure was 40 psi, the sheath gas temperature was 350°C, the sheath gas flow rate was 11 L / min, the threshold was set to 100 (1%), the nozzle voltage was 2 kV, the capillary voltage was 3.5 kV, the fragmentor voltage was 380 V, and the collision energy was set to Collision Energy = -1.586 (m / z) / 100 + 54.49; the MS scan range was m / z 720-1300, and the acquisition rate was 3 spectra / s; the MS / MS scan range was m / z 50-1500, and the acquisition rate was 4 spectra / s; the separation width was medium (~4 m / z), and the top 3 strong ions in each primary mass spectrometry data were selected for secondary mass spectrometry fragmentation.
[0055] Accurately weigh the dehydrated safflower yellow B (anHSYB) standard to prepare a 1 mg / mL reference stock solution, add appropriate amount of pure water to dilute it into a series of solutions containing 1 μg, 5 μg, 25 μg, 125 μg, 250 μg, and 500 μg per 1 mL, and collect under the same chromatographic conditions as above.
[0056] Waters I-Class UPLC / Vion TM The BPI map of m / z720-1300 was collected by IM-QTOF high-resolution ion mobility liquid chromatography-mass spectrometry ( Figure 1 ) It can be seen that, compared with the alcohol extract as a reference, the peak of the 40% ethanol eluate has the highest similarity with it, and the peak area of the target component accounts for the largest proportion (as shown in Table 1), indicating that this fraction effectively enriches the chalcone dimer components in the alcohol extract. According to the results collected by 1290 ultra-high performance liquid chromatograph, the peak area of the reference substance is used as the ordinate (Y) and the concentration of the reference substance (mg / mL) is used as the abscissa (X), and the standard curve is drawn to obtain the linear regression equation y=26079x+66.992, and the linear regression equation coefficient R 2 The linear relationship is 0.9998, which is good within the experimental investigation range. The content of anHSYB in safflower alcohol extract and each fraction was calculated by linear regression equation, and the TIC graph of m / z 720-1300 of each sample collected by 1290Infinity II / 6550QTOF high-resolution liquid chromatography-mass spectrometer and the chromatogram at 405nm were combined to attribute the chalcone dimer at 405nm of 1290 ultra-high performance liquid chromatograph, and the total chalcone dimer content was further calculated by its total peak area. The results are shown in Table 2. It can be seen that the total chalcone dimer content in the 40% v / v ethanol aqueous solution eluate obtained by HPD100 column chromatography enrichment of safflower alcohol extract is relatively high, indicating that the enrichment method is effective.
[0057] Table 1 Peak area ratio of target components in each fraction of safflower at the same concentration
[0058]
[0059] Table 2 Total chalcone dimer content in each fraction of safflower
[0060]
[0061] Test Example 2
[0062] Elution fractions were prepared using different macroporous adsorption resins (specifications: inner diameter 4 cm, column height 32 cm): the ethanol extract of safflower prepared according to the method of S1 in Example 1 was fully dissolved with pure water by ultrasound and then loaded on the samples for adsorption for 2 hours. Pure water, 10%, 30%, 50%, 70% and 95% v / v ethanol aqueous solution were used for isocratic elution for 4 column volumes each, and each eluent was used for 4 fractions, each fraction was 1 column volume, and finally a total of 24 fractions were obtained for each filler.
[0063] The fractions obtained from D101, AB-8, X-5, ADS-7, HPD100, and MCI macroporous adsorption resins were further combined after detection by 1290 ultra high performance liquid chromatograph. After the combination, D101 was 11 fractions, X-5 was 11 fractions, ADS-7 was 8 fractions, HPD100 was 8 fractions, AB-8 was 8 fractions, and MCI was 10 fractions. They were detected by QDA respectively, and the strongest response intensity and proportion of components with a mass number >950 in each fraction were compared by extracting 32 mass numbers with the total extract as a reference. The fractions of ADS-17, D4020, and HPD200A macroporous adsorption resins were detected on a 1260 semi-preparative liquid chromatograph. The fractions from the above different fillers were combined based on the peaks at 405 nm of each fraction. The fractions obtained after combining the fillers were detected on an Agilent 1260 InfinityⅡ / 6125B LC-MS / MS.
[0064] The chromatographic conditions for detection using an Agilent 1290 ultra-high performance liquid chromatograph were as follows: the chromatographic column was ACQUITY HSS T3 (2.1×100mm, 1.8μm); column temperature 25℃; mobile phase A was 0.1% formic acid aqueous solution, mobile phase B was CH3CN, flow rate was 0.3mL / min, injection volume was 3μL, wavelengths were set to 254, 280, 320, and 405nm, and elution was performed according to the gradient elution program: 0-3min, 1%-13% (B); 3-7min, 13%-16% (B); 7-8min, 16%-19% (B); 8-12min, 19%-26% (B); 12-14min, 26%-50% (B); 14-15min, 50%-95% (B).
[0065] The chromatographic conditions for the Waters I-Class UPLC / QDA LC / MS were as follows: sample concentration was 100 mg / mL, and the chromatographic column was ACQUITY HSS T3 (2.1×100mm, 1.8μm), column temperature 25℃; mobile phase A is 0.1% formic acid aqueous solution, mobile phase B is CH3CN, flow rate is 0.3mL / min, injection volume is 5μL, wavelengths are set at 254, 280, 320, 405nm, and elution is performed according to the gradient elution program: 0-3min, 1%-13% (B); 3-7min, 13%-16% (B); 7-8min, 16%-19% (B); 8-12min, 19%-26% (B); 12-14min, 26%-40% (B); 14-16min, 40%-48% (B); 16-17min, 48%-95% (B). Negative ion mode detection; scanning range MS: m / z 100-1250.
[0066] The chromatographic conditions for detection using an Agilent 1260 InfinityⅡ high performance liquid chromatograph were as follows: sample concentration was 40 mg / mL, chromatographic column was HSS T3 (3.0×150mm, 3.5μm); column temperature 25°C; mobile phase A was 0.1% formic acid aqueous solution, mobile phase B was 0.1% FA-CH3CN, flow rate was 0.6mL / min, injection volume was 5μL, wavelengths were set to 254 and 405nm, and elution was performed according to the gradient elution program: 0-2min, 1%-13% (B); 2-10min, 13%-17% (B); 10-17min, 17%-24% (B); 17-19min, 24%-30% (B); 19-22min, 30%-55% (B); 22-25min, 55%-65% (B); 25-29min, 65%-95% (B) and 29-32min, 95% (B); an equilibrium time of 6min was set between consecutive injections.
[0067] The chromatographic conditions for the Agilent 1260 InfinityⅡ / 6125B LC / MS were as follows: sample concentration was 40 mg / mL and the chromatographic column was Waters XSelect HSS T3 chromatographic column (3.0×150mm, 3.5μm), column temperature 25℃, mobile phase A was 0.1% formic acid aqueous solution, mobile phase B was CH3CN, flow rate was 0.6mL / min, wavelength range was 190-500nm, four wavelengths of 254, 280, 320, and 405nm were selected, and elution was performed according to the gradient program: 0-2min, 1%-13% (B); 2-10min, 13%-17% (B); 10-17min, 17%-24% (B); 17-19min, 24%-30% (B); 19-22min, 30%-55% (B); 22-25min, 55%-65% (B); 25-29min, 65%-95% (B) and 29-32min, 95% (B), and an equilibrium time of 6min was set between consecutive injections. Negative ion mode detection; scanning range MS: m / z 100-1500; ion source: ESI; source fragmentation voltage: 70V.
[0068] The results showed that the number of peaks with mass numbers greater than 950 extracted by HPD100, D101 and AB-8 was relatively large. Among them, the proportion of mass numbers > 950 in the HPD100 fraction was the largest and the strongest response intensity was close to the response intensity of the corresponding mass number in the total extract; the strongest response intensity of the peaks in the D101, AB-8 and MCI fractions was better than the response intensity of the corresponding mass number in the total extract, but the proportion of mass numbers > 950 was slightly lower than that of HPD100; while the response of compounds with mass numbers above 950 detected in the fractions of ADS-7 and X-5 fillers was relatively small (such as Figure 2 With the total extract as a reference, the response of each fraction of each column was compared by extracting the fixed mass number, as shown in Figure 3 Taking m / z 1115.25, 1043.27 and 955.21 as examples, it can be seen that the HPD100 and D101 column chromatographic fractions have the strongest response and the chromatographic peaks are similar to those of the total extract. Among the fractions, the peaks in the fractions eluted with 30% ethanol and 50% ethanol are better separated, with complete peak shapes and stronger response intensities.
[0069] The results of the combined fractions of ADS-17, D4020, and HPD200A macroporous adsorption resin fillers are shown in Table 3 (* indicates the main distribution of the target component). From the perspective of the target fraction weight, the column chromatography of the three fillers has the best enrichment effect on this type of component. HPD200A is second. Taking the total extract as a reference, the response of each fraction of each chromatographic column is compared by extracting the mass number of a fixed value, and plotting m / z1115.25, 1043.27, and 955.21 as examples (see Figure 3). Figure 4 As shown), it can be seen that the D4020 column chromatographic fraction has the strongest response and the largest number of isomer chromatographic peaks.
[0070] Table 3 Comparison of the enrichment effects of three macroporous adsorption resin fillers on target components
[0071]
[0072]
[0073] From the above results, it can be seen that HPD100 and D4020 fillers have the best enrichment effect on chalcone dimer components.
[0074] HPD100 and D4020 macroporous adsorption resin fillers were selected and further eluted with pure water, 10%, 20%, 30%, 40%, 50%, and 95% v / v ethanol aqueous solution according to the subdivided elution gradient to evaluate the dimer enrichment. Take about 18.0g of safflower ethanol extract prepared according to S1 in Example 1, fully dissolve it with 35mL pure water, and then load it separately for adsorption for 2h. Elute 5 column volumes in each subdivided gradient in turn, 1 column volume for each fraction, and merge the fractions eluted with the same gradient. Finally, a total of 7 fractions were obtained for each filler, and the obtained fractions were detected on an Agilent 1260InfinityⅡ / 6125B LC-MS instrument.
[0075] A larger open column (specification: inner diameter of 10 cm, column height of 60 cm) was used for a scale-up experiment to compare the enrichment effects of HPD100 and D4020: 80 g of safflower ethanol extract prepared according to S1 in Example 1 was taken, fully dissolved in 100 mL of pure water, adsorbed for 2 h, and eluted according to the elution gradient of pure water, 10%, 20%, 30%, 40%, 50%, and 95% ethanol, respectively. The fractions eluted with the same gradient were combined, and finally 7 fractions were obtained for each filler. The obtained fractions were detected on an Agilent 1260 InfinityⅡ / 6125B LC-MS / MS instrument.
[0076] From the weight of the key fractions of safflower in Table 4 (* indicates the main distribution of the target component), HPD100 has a better enrichment effect on dimers than D4020. The number of peaks extracted from each fraction of the two column chromatograms and the response were compared by the target mass number that appeared when the extraction conditions were optimized (Table 5). From the number of peaks and the response, HPD100 is better than D4020; Figure 5 Taking the extraction of m / z952 and 1043 as an example, the number of peaks in each fraction of the two column chromatography and the fraction with the best response are shown. In summary, the best enrichment effect of chalcone dimer components among the nine macroporous adsorption resin fillers is HPD100, and this type of component is mainly in the 10%, 20%, 30%, and 40% ethanol eluents. The enrichment yield of different parts by HPD100 column chromatography is shown in Table 6.
[0077] Table 4 Comparison of the enrichment effect of target components by HPD100 and D4020 macroporous adsorption resin fillers
[0078]
[0079]
[0080] Table 6 The yield of different parts enriched by HPD100 column chromatography
[0081]
[0082] Test Example 3
[0083] The safflower alcohol extract was prepared with reference to the steps of S1 in Examples 1 to 4 using methanol of different concentrations as the extraction solvent: safflower powder (500 mg) was accurately weighed and soaked in 6 mL of four different concentrations of methanol for 24 h. Then, the sample was extracted on a 40°C water bath with the assistance of ultrasound (400 W, 37 kHz) for 30 min, and 4 mL of the same solvent was ultrasonicated for 30 min for the second time, followed by centrifugation of the extract at 3,000 rpm for 10 min, and then the supernatant was transferred to a 10 mL volumetric flask. A 50% v / v methanol aqueous solution was added to the calibration line as a supplement. The safflower water extract was prepared according to the same parameters: safflower powder (500 mg) was accurately weighed and soaked in 6 mL of pure water for 24 h, and then the sample was extracted on a 40°C water bath with the assistance of ultrasound (400 W, 37 kHz) for 30 min, and then 4 mL of pure water was ultrasonicated for 30 min, and then the extract was centrifuged at 3,000 rpm for 10 min, and then the supernatant was transferred to a 10 mL volumetric flask and added to the calibration line with water. The test solution was diluted to a concentration of 10 mg / mL (based on crude drug) and centrifuged at 14,000 rpm (11,481 × g) for 10 minutes. The peak numbers and peak areas of the target components in different extraction solvents were compared by 1290 Infinity II / 6550 QTOF high-resolution LC / MS.
[0084] The chromatographic column is HSS connected to a VanGuard pre-column (2.1×50mm, 1.7μm) T3 (2.1×100mm, 1.8μm); column temperature: 30℃; mobile phase: phase A is 0.1% formic acid aqueous solution, phase B is acetonitrile; flow rate: 0.3mL / min; injection volume: 3μL; elution was performed according to the gradient elution program: 0-4min, 1%-13% (B); 4-9min, 13%-16% (B); 9-11min, 16%-19% (B); 11-16min, 19%-26% (B); 16-19min, 26%-35% (B); 19-23min, 35%-45% (B); 23-24min, 45%-95% (B) and 24-26min, 95% (B); a 4min equilibrium time was set between consecutive injections.
[0085] Auto MSMS was used as the acquisition method, and the data were collected in negative ion scanning mode. The mass spectrometer parameters in the Auto MSMS (Seg) mode were set as follows: ultra-high purity nitrogen (N2) and nitrogen generated by a nitrogen generator were used as collision gas and sheath gas / auxiliary gas, respectively; the gas temperature was set to 200°C, the drying gas flow rate: 12 L / min, the nebulizer pressure: 40 psi, the sheath gas temperature: 350°C, the sheath gas flow rate: 11 L / min, the threshold was set to 100 (1%), the nozzle voltage was 2 kV, the capillary voltage was 3.5 kV, the fragmentor voltage was 380 V, and the collision energy was set to Collision Energy = -1.586 (m / z) / 100 + 54.49; the MS scan range was m / z 100-1500, and the acquisition rate was 3 spectra / s; the MS / MS scan range was m / z 50-1500, and the acquisition rate was 4 spectra / s; the separation width was medium (~4 m / z), and the top 3 strong ions were selected in each primary mass spectrometry data for secondary mass spectrometry fragmentation.
[0086] According to statistics, the target component has the largest number of peaks in 50% methanol (v / v), and the total peak area of the known target components is the highest, as shown in Tables 7 and 8.
[0087] Table 7 Comparison of the peak numbers of target components under different extraction solutions
[0088]
[0089] Table 8 Comparison of peak areas of known target component mass numbers under different extraction solvents
[0090]
[0091] Example 5
[0092] This example provides the use of the extract prepared in Example 1 in in vitro anticoagulation.
[0093] 1. Preparation of plasma to be tested
[0094] Male SD rats were intraperitoneally injected with 20% urethane (5 mL / kg body weight, prepared on the spot), and blood was collected from the abdominal aorta. The whole blood was placed in a blood collection tube containing 3.2% sodium citrate anticoagulant solution at a volume ratio of 9:1 and mixed thoroughly. The tube was gently inverted and mixed 8 times to prevent coagulation. The tube was centrifuged at 3,000 rpm for 15 minutes, and the upper plasma was collected and placed on ice for testing.
[0095] 2. Preparation of sample solution
[0096] The safflower alcohol extract was prepared according to the operation of S1 in Example 1. 18 g of safflower alcohol extract was dissolved in 15 mL of pure water by ultrasonication, and added to a HPD100 macroporous adsorption resin column (with an inner diameter of 2.0 cm and a column height of 32 cm). After adsorbing for 2 h, elution was performed using 2 L of pure water and 40%, 50%, 60%, and 95% v / v ethanol aqueous solutions in sequence. The eluates were collected, concentrated under reduced pressure below 40° C., and then freeze-dried into powder.
[0097] Accurately weigh the above safflower alcohol extract and enriched fractions (the eluents are pure water, 40% v / v ethanol aqueous solution, 50% v / v ethanol aqueous solution, 60% v / v ethanol aqueous solution, 95% v / v ethanol aqueous solution), and dissolve them in 10% DMSO solution to prepare solutions with a concentration of 30.0 mg / mL. Take the reference substance pharmacopoeia index components kaempferol, hydroxysafflower yellow, chalcone dimer safflower yellow, and dehydrated safflower yellow B and dissolve them in 10% DMSO solution to prepare solutions with a concentration of 1.00 mg / mL, and store them in a 4°C refrigerator for use. Mix the plasma to be tested with each drug group of safflower, the positive control group, and the control group (10% DMSO solution) at a volume of 4:1 to form 1 mL of sample solution, number them in sequence, and complete the test within 2-3 hours.
[0098] 3. Determination of APTT, TT, PT and FIB
[0099] Use ellagic acid solution to mix and preheat at 37℃ for a certain period of time. With the participation of calcium ions, the endogenous coagulation system is activated to convert fibrinogen into insoluble fibrin. The time required for coagulation is measured, which is the activated partial thromboplastin time (APTT). Add an appropriate amount of thrombin to the plasma to activate the common coagulation pathway, converting fibrinogen into insoluble fibrin. The time for the appearance of fibrin filaments is the thrombin time (TT). Add an excess of tissue thromboplastin (tissue factor) to the plasma to be tested. 2+ The prothrombin is converted into thrombin under the participation of the tester, and the soluble fibrinogen is converted into insoluble fibrin. The time required for coagulation is measured, which is the prothrombin time (PT) of the plasma to be tested. Excessive thrombin is added to the plasma to convert fibrinogen into insoluble fibrin, thereby coagulating. The coagulation time of plasma is negatively correlated with the fibrinogen content. The content of fibrinogen (FIB) in plasma can be obtained by establishing a standard curve. According to the operating procedures of the fully automatic coagulation instrument, each group of sample solutions is measured, and the APTT, TT, PT and FIB values are recorded.
[0100] All measured values were expressed as mean ± SD, and all grouped data were statistically analyzed using SPSS21.0. When the normality test was met, one-way analysis of variance and LSD (homogeneous variance) and Dunnett's T3 (uneven variance) tests were used to evaluate the significant differences between the data groups. When the normality test was not met, independent samples of nonparametric tests were used to evaluate the significant differences between the data groups. GraphPad Prism software was used to make statistical graphs.
[0101] The results are shown in Table 9 below.
[0102] Table 9 Effects of different safflower fractions on in vitro anticoagulant activity (mean ± SD, n = 3)
[0103]
[0104] Note: Compared with the blank control group, * P<0.05, ** P<0.01, *** P<0.001
[0105] Compared with the blank group, the 40% v / v ethanol aqueous solution eluate can significantly prolong APTT, PT and TT, and significantly reduce the FIB content, indicating that it can simultaneously activate the intrinsic, common coagulation pathways and extrinsic coagulation systems to exert anticoagulant function, and has the effect of significantly increasing the activity of rat plasma plasminogen activator, and the effect on PT is the most significant (P<0.001), TT is significant (P<0.01), and APTT is second (P<0.05). In addition, the 50% v / v ethanol aqueous solution eluate can also significantly prolong APTT, PT and TT, but has little effect on the FIB content, indicating that its anticoagulant function pathway is similar to that of the 40% v / v ethanol aqueous solution eluate, but has little effect on the activity of rat plasma plasminogen activator. The other fractions cannot be considered to be different from the blank group, but there are certain changes, and have a certain anticoagulant effect. It can be seen that the anticoagulant active components in the safflower extract are mainly enriched in the 40% ethanol eluate and the 50% ethanol eluate after separation by macroporous resin.
[0106] In addition, the differences in anticoagulant activity among flavonoids represented by kaempferol, quinone chalcone monomers represented by HSYA, and quinone chalcone dimers represented by SY and anHSYB are shown in Table 10.
[0107] Table 10 Effects of four representative compounds of safflower on in vitro anticoagulant activity (mean ± SD, n = 3)
[0108]
[0109] Note: Compared with the blank control group,* P<0.05, ** P<0.01, *** P<0.001
[0110] As shown in Table 10, compared with the blank group, 1 mg / mL kaempferol can significantly prolong APTT and PT, SY can significantly prolong APTT, and anHSYB can significantly prolong PT and TT, indicating that kaempferol can activate the endogenous and exogenous coagulation systems to exert anticoagulant function, SY can activate the endogenous anticoagulant effect, and anHSYB can activate the exogenous coagulation system and the common coagulation pathway to exert anticoagulant function. The three have different functions in the coagulation pathway. The results of the APTT experiment showed that HSYA showed a slight anticoagulant effect, but the statistical results showed that there was no significant difference with the blank control.
[0111] Example 6
[0112] This example provides the use of the extract prepared in Example 1 in anti-platelet aggregation.
[0113] 1. Sample preparation
[0114] The ethanol extract of safflower and the enriched fractions in Example 5 were respectively prepared into 10% DMSO solutions with concentrations of 2.0, 1.5, 1.0, 0.50, 0.25, and 0.10 mg / mL as test samples. The reference substances kaempferol, safflower yellow, dehydrated safflower yellow B, and hydroxysafflower yellow A were prepared into 10% DMSO solutions with concentrations of 1.0, 0.5, 0.1, 0.02, 0.004, and 0.0008 mg / mL as test samples.
[0115] 2. Preparation of reagents
[0116] HEPES buffer is prepared on demand and consists of 145mM sodium chloride, 5mM potassium chloride, 12mM sodium bicarbonate, 0.5mM sodium dihydrogen phosphate, 5mM HEPES, 5.6mM glucose and 0.35% bovine serum albumin, dissolved in ultrapure water, and adjusted to pH = 7.4 with 0.1M NaOH. The washing solution PGE1 solution is prepared with anhydrous ethanol as its storage solution and diluted to 0.2μM with buffer. The anhydrous calcium chloride solution is prepared with buffer to 1mg / mL. The agonist ADP solution is dissolved in saline and diluted to a concentration of 7μM with 1mg / mL anhydrous CaCl2 solution. The positive drug ticaregg is dissolved in anhydrous ethanol to make a 1mg / mL stock solution and then diluted to 4μM with buffer.
[0117] 3. Preparation of resuspended platelets
[0118] Blood was collected from the abdominal aorta of anesthetized male SD rats by intraperitoneal injection of 20% ulanose (5 mL / kg, prepared and used immediately). The whole blood was placed in a blood collection tube containing 3.2% sodium citrate anticoagulant solution and gently inverted and mixed 8 times in a volume ratio of 9:1 to prevent coagulation. After standing for 3 minutes, the whole blood was centrifuged at 800 rpm for 20 minutes at room temperature, the precipitate containing red blood cells and white blood cells was discarded, and the supernatant was taken to obtain the platelet-rich plasma (PRP) final volume solution. It was centrifuged at 3000 rpm for 10 minutes at room temperature to obtain platelet precipitates, and 0.2 μM / L PGE1 solution was added for washing, and centrifuged at 3000 rpm for 10 minutes at room temperature three times, and PGE1 solution was added while discarding the supernatant each time, and then the obtained platelet precipitate was resuspended in HEPES buffer, and the final volume of the buffer added was 10:6 to the final volume of PRP solution.
[0119] 4. Antiplatelet aggregation effect test method
[0120] The sample solutions and dosages added to the negative group, blank group, ticareg group, 10 drug groups (safflower alcohol extract, safflower pure water, 40%, 50%, 60%, 95% ethanol elution fractions, kaempferol, HSYA, SY, anHSYB) and the background group are shown in Table 11.
[0121] Table 11 Experimental groups and the amount of each sample solution in the test sample
[0122]
[0123]
[0124] In the platelet aggregation reaction of the 96-well ELISA plate, when the platelets and the drug react to produce an aggregation reaction, the turbidity of the corresponding platelet system decreases, that is, the absorbance value decreases. Therefore, the change in the external absorbance value can reflect the aggregation of platelets. In addition to the agonist, platelets, test samples, buffer, etc. are added to the 96-well plate, and then placed in a multifunctional ELISA instrument, incubated at 37°C for 13 minutes to wait for the platelets and the drug to fully react and fuse, then the 96-well plate is taken out and the agonist is quickly added with a multi-hole pipette, and the temperature is kept constant and shaken. The reading is read every 30 seconds, and the oscillation is performed for 30 seconds during the period. The absorbance OA value of each well within 30 minutes is continuously detected, and it can be stopped at 30 minutes. The detection wavelength is 405nm. The software exports the experimental data. The OA value of each well at each time point is analyzed in Office Excel, and the platelet aggregation rate and drug aggregation inhibition rate of different drugs and different concentration experimental groups are calculated according to formulas (1, 2).
[0125] Platelet aggregation rate (%) = (OD t=0 -OD t ) / OD t=0×100% (1)
[0126] Platelet aggregation inhibition rate (%) = [(maximum aggregation rate of negative group - maximum aggregation rate of blank group) - (maximum aggregation rate of experimental group - maximum aggregation rate of blank group)] / (maximum aggregation rate of negative group - maximum aggregation rate of blank group) × 100% (2)
[0127] Where: OD t=0 is the measured initial OD value, OD t It is the OD value at the end of the test, and the maximum aggregation rate is the value when the platelet aggregation reaction is complete or reaches the preset reaction time.
[0128] All measured values were expressed as mean ± SD, and all grouped data were statistically analyzed using SPSS21.0. When the normality test was met, one-way analysis of variance and LSD (homogeneous variance) and Dunnett's T3 (uneven variance) tests were used to evaluate the significant differences between the data groups. When the normality test was not met, independent samples of nonparametric tests were used to evaluate the significant differences between the data groups. GraphPad Prism software was used to make statistical graphs.
[0129] The results of the effects of safflower alcohol extract, its fractions and monomer compounds on ADP-induced platelet aggregation in rats are shown in Table 12.
[0130] Table 12 Effects of different safflower extracts on platelet aggregation (mean ± SD, n = 3)
[0131]
[0132]
[0133] After the platelets fully reacted with the drug and fused, the platelet aggregation reaction in each group was complete within 10 minutes. Figure 6As shown, the maximum aggregation rate was obtained. Compared with the blank group, the platelet aggregation rate of the negative group increased significantly, indicating that the model was successful. Compared with the negative group, except for the 0.1 mg / mL drug group, the platelet aggregation rate of each group decreased and had significant differences, indicating that each drug group had a certain anti-platelet aggregation effect. The key fraction 40% v / v ethanol aqueous solution eluate was compared with other fractions. When the drug concentration was 0.10, 0.25, and 0.50 mg / mL, the platelet aggregation rate of 50%, 60%, and 95% v / v ethanol aqueous solution eluate was significantly different from that of 40% v / v ethanol aqueous solution eluate (P<0.05), and the aggregation rate of 40% v / v ethanol aqueous solution extract was the lowest. When the drug concentration was 0.50 and 1.0 mg / mL, the aggregation rate was even lower than that of the alcohol extract, while the pure water eluate was significantly different from it only at 1.0 mg / mL, and there was no significant difference between the two at other concentrations (P>0.05). However, the aggregation effect of the pure water eluate was relatively high. When the concentration of the drug group reached 1.5 mg / mL, the platelet aggregation rate of each group was low, indicating that the effective components in safflower that exert anti-platelet aggregation effect are mainly enriched in the 40% v / v ethanol aqueous solution eluate, and a low concentration can achieve a good anti-platelet aggregation effect. The results are shown in Figure 7 .
[0134] For the four representative components in safflower ( Figure 8 ), compared with the negative group, the platelet aggregation rate of each group was reduced and there were extremely significant differences (P<0.01), indicating that they all had a certain anti-platelet aggregation effect. Compared with kaempferol, a representative of flavonoids, HSYA and SY had significant differences at concentrations of 0.10, 0.50 and 1.0 mg / mL, and the platelet aggregation rate was low. Among them, HSYA had no significant difference with it at the other three low concentrations (P>0.05), SY had significant differences at concentrations of 0.004 and 0.02 mg / mL, but the aggregation effect was relatively high, and anHSYB had a lower aggregation rate than kaempferol only at a concentration of 1.0 mg / mL, indicating that the anti-platelet aggregation effect of these three components was obvious when they reached a certain concentration.
[0135] The platelet aggregation inhibition rate was used as the evaluation index for the antiplatelet aggregation rate. Fig. 9 The relationship between the antiplatelet aggregation rate and concentration of each drug group is intuitively demonstrated. It can be seen that the antiplatelet aggregation effect of the 40% v / v ethanol aqueous solution eluate is similar to or even better than that of the alcohol extract, and the pure water eluate and the 40% v / v ethanol aqueous solution eluate can achieve good inhibitory effects at low concentrations. For representative ingredients, the concentration has little effect on the antiplatelet aggregation effect of kaempferol, while the platelet aggregation inhibition rate of the other three ingredients is relatively high at a concentration of 1.0 mg / mL and above. Comparison of IC 50 Value and combine Fig. 9It was found that the 40% v / v ethanol aqueous solution eluate in the fraction and HSYA and SY among the representative compounds had better anti-platelet aggregation effects.
[0136] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the present invention.
Claims
1. A method for enriching quinone chalcone dimer compounds in safflower, It is characterized in that The specific steps include: S1. extracting safflower with methanol or ethanol, and drying the obtained extract to obtain safflower alcohol extract; S2. Performing column chromatography on the safflower alcohol extract using a macroporous adsorption resin, eluting with pure water and 10% to 50% v / v ethanol aqueous solution in sequence, collecting the eluate eluted with 10% to 50% v / v ethanol aqueous solution, and drying to obtain; the macroporous adsorption resin is HPD100 or D4020 macroporous adsorption resin.
2. The enrichment method according to claim 1, It is characterized in that The concentration of methanol or ethanol in S1 is not less than 30% v / v.
3. The enrichment method according to claim 2, It is characterized in that The concentration of methanol or ethanol in S1 is 50% to 80% v / v; and / or In S1, safflower is extracted with ethanol.
4. The enrichment method according to any one of claims 1 to 3, It is characterized in that The macroporous adsorption resin in S2 is HPD100 macroporous adsorption resin.
5. The enrichment method according to any one of claims 1 to 3, It is characterized in that The concentration of the ethanol aqueous solution in S2 is 40% v / v.
6. A safflower extract having anticoagulant activity, It is characterized in that The safflower extract is prepared by the enrichment method according to any one of claims 1 to 5.
7. Use of the safflower extract according to claim 6 in the preparation of anticoagulant drugs.
8. The use according to claim 7, It is characterized in that The anticoagulant drug is an in vitro anticoagulant drug.
9. The use according to claim 7, It is characterized in that The anticoagulant drug is a drug that increases the activity of plasma fibrinolytic enzyme.
10. The use according to claim 7, It is characterized in that The anticoagulant drug is a drug that prevents platelet aggregation.
